Susquehanna International Group
NAVB

Susquehanna International Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Susquehanna International Group’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-125,866
Closed -$11.6K – 13511
2023
Q2 		$11.6K Buy
+125,866
New +$20.1K ﹤0.01% 11738
2021
Q4 		– Sell
-43,445
Closed -$61.1K – 14531
2021
Q3 		$76K Buy
43,445
+1,513
+4% +$2.55K ﹤0.01% 12201
2021
Q2 		$77K Buy
41,932
+29,615
+240% +$52.3K ﹤0.01% 12191
2021
Q1 		$25K Sell
12,317
-1,071
-8% -$2.51K ﹤0.01% 12125
2020
Q4 		$29K Buy
+13,388
New +$31.6K ﹤0.01% 10850
2020
Q3 		– Sell
-46,921
Closed -$168K – 11545
2020
Q2 		$185K Buy
+46,921
New +$89.7K ﹤0.01% 9115
2018
Q1 		– Sell
-699
Closed -$5K – 10684
2017
Q4 		$5K Sell
699
-3,612
-84% -$30.6K ﹤0.01% 9131
2017
Q3 		$35K Buy
4,311
+2,169
+101% +$18.4K ﹤0.01% 8600
2017
Q2 		$22K Sell
2,142
-1,842
-46% -$18.2K ﹤0.01% 9013
2017
Q1 		$46K Buy
3,984
+2,679
+205% +$30.4K ﹤0.01% 8618
2016
Q4 		$16K Sell
1,305
-8,442
-87% -$134K ﹤0.01% 9449
2016
Q3 		$179K Sell
9,747
-731
-7% -$9.25K ﹤0.01% 7664
2016
Q2 		$111K Buy
10,478
+7,520
+254% +$148K ﹤0.01% 7973
2016
Q1 		$55K Sell
2,958
-304,989
-99% -$5.87M ﹤0.01% 8644
2015
Q4 		$8.19M Sell
307,947
-3,440
-1% -$119K ﹤0.01% 1956
2015
Q3 		$14.2M Buy
311,387
+3,850
+1% +$145K 0.01% 1495
2015
Q2 		$9.9M Buy
307,537
+3,333
+1% +$96.8K ﹤0.01% 2013
2015
Q1 		$9.67M Sell
304,204
-11,990
-4% -$406K ﹤0.01% 1918
2014
Q4 		$12M Buy
316,194
+4,839
+2% +$133K ﹤0.01% 1836
2014
Q3 		$8.22M Sell
311,355
-6,101
-2% -$161K ﹤0.01% 2333
2014
Q2 		$9.4M Sell
317,456
-7,766
-2% -$251K ﹤0.01% 2192
2014
Q1 		$12M Buy
325,222
+273,558
+529% +$10.4M 0.01% 1793
2013
Q4 		$2.14M Buy
51,664
+40,191
+350% +$1.57M ﹤0.01% 4158
2013
Q3 		$608K Sell
11,473
-6,199
-35% -$361K ﹤0.01% 6132
2013
Q2 		$944K Buy
+17,672
New +$882K ﹤0.01% 5088

Other funds holding NAVB

ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group's NAVB Position: Q3 2023 in Review

Susquehanna International Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2023, closing a stake of 125,866 shares — an estimated $11.6K sold.

Susquehanna International Group first reported a position in NAVB in Q2 2013 and held it in 25 quarters. The position peaked at $14.2M in Q3 2015. 24 funds tracked by Wall St. Rank hold NAVB as of Q3 2023.

  • Susquehanna International Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2023 after selling out during the quarter.
  • Susquehanna International Group sold 125,866 Navidea Biopharmaceuticals Inc. shares in Q3 2023, an estimated $11.6K.
  • Susquehanna International Group first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 25 quarters.
  • Susquehanna International Group's Navidea Biopharmaceuticals Inc. position peaked at $14.2M in Q3 2015.
  • 24 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.